Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.

Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T, Kodama M, Ishihara T, Kuroda S.

J Clin Psychiatry. 2008 Sep;69(9):1416-22.

PMID:
19193342
2.

Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.

Gunes A, Melkersson KI, Scordo MG, Dahl ML.

J Clin Psychopharmacol. 2009 Feb;29(1):65-8. doi: 10.1097/JCP.0b013e31819302c3.

PMID:
19142110
3.
4.

Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia.

Ellingrod VL, Bishop JR, Moline J, Lin YC, Miller DD.

Psychopharmacol Bull. 2007;40(1):57-62.

PMID:
17285096
5.

Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients.

Park YM, Cho JH, Kang SG, Choi JE, Lee SH, Kim L, Lee HJ.

J Clin Pharm Ther. 2008 Feb;33(1):55-60. doi: 10.1111/j.1365-2710.2008.00872.x.

PMID:
18211617
6.

Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.

Alenius M, Wadelius M, Dahl ML, Hartvig P, Lindström L, Hammarlund-Udenaes M.

J Psychiatr Res. 2008 Sep;42(11):884-93. Epub 2007 Dec 20.

PMID:
18086475
7.

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.

Laika B, Leucht S, Heres S, Schneider H, Steimer W.

Pharmacogenomics J. 2010 Feb;10(1):20-9. doi: 10.1038/tpj.2009.32. Epub 2009 Jul 28.

PMID:
19636338
8.

Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.

Houston JP, Kohler J, Bishop JR, Ellingrod VL, Ostbye KM, Zhao F, Conley RR, Poole Hoffmann V, Fijal BA.

J Clin Psychiatry. 2012 Aug;73(8):1077-86. doi: 10.4088/JCP.11m06916.

PMID:
22967772
9.

HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.

Ma X, Maimaitirexiati T, Zhang R, Gui X, Zhang W, Xu G, Hu G.

Int J Psychiatry Clin Pract. 2014 Oct;18(4):229-42. doi: 10.3109/13651501.2014.957705. Epub 2014 Sep 18.

PMID:
25152019
10.

The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients.

Kuzman MR, Medved V, Bozina N, Hotujac L, Sain I, Bilusic H.

Psychiatry Res. 2008 Sep 30;160(3):308-15. doi: 10.1016/j.psychres.2007.06.006. Epub 2008 Aug 20.

PMID:
18718676
11.

Risperidone-related weight gain: genetic and nongenetic predictors.

Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT, Chang WH.

J Clin Psychopharmacol. 2006 Apr;26(2):128-34.

PMID:
16633140
12.
13.

Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment.

Park YM, Chung YC, Lee SH, Lee KJ, Kim H, Byun YC, Lim SW, Paik JW, Lee HJ.

Am J Med Genet B Neuropsychiatr Genet. 2006 Jun 5;141B(4):394-7.

PMID:
16583406
14.

DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain.

Popp J, Leucht S, Heres S, Steimer W.

Pharmacogenomics J. 2009 Feb;9(1):71-7. doi: 10.1038/tpj.2008.5. Epub 2008 Mar 11.

PMID:
18332898
15.

Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene.

Godlewska BR, Olajossy-Hilkesberger L, Ciwoniuk M, Olajossy M, Marmurowska-Michałowska H, Limon J, Landowski J.

Pharmacogenomics J. 2009 Aug;9(4):234-41. doi: 10.1038/tpj.2009.18. Epub 2009 May 12.

PMID:
19434072
16.

-759C>T Polymorphism of the HTR2C Gene is Associated with Second Generation Antipsychotic-Induced Weight Gain in Female Patients with Schizophrenia.

Daray FM, Rodante D, Carosella LG, Silva ME, Martínez M, Fernández Busch MV, Faccone DF, Rothlin RP, Maffía PC.

Pharmacopsychiatry. 2017 Jan;50(1):14-18. doi: 10.1055/s-0042-110321. Epub 2016 Jul 14.

PMID:
27414739
17.

Weight gain during treatment of bipolar I patients with olanzapine.

Hennen J, Perlis RH, Sachs G, Tohen M, Baldessarini RJ.

J Clin Psychiatry. 2004 Dec;65(12):1679-87.

PMID:
15641874
18.

-759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment.

Ryu S, Cho EY, Park T, Oh S, Jang WS, Kim SK, Lee D, Hong KS.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):673-7. Epub 2007 Jan 12.

PMID:
17275977
19.

A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.

Lee SY, Park MH, Patkar AA, Pae CU.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):490-6. doi: 10.1016/j.pnpbp.2010.12.003. Epub 2010 Dec 10.

PMID:
21146575
20.

A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia.

Gonçalves VF, Zai CC, Tiwari AK, Brandl EJ, Derkach A, Meltzer HY, Lieberman JA, Müller DJ, Sun L, Kennedy JL.

Neuropsychopharmacology. 2014 May;39(6):1347-54. doi: 10.1038/npp.2013.312. Epub 2013 Nov 7.

Supplemental Content

Support Center